TG TherapeuticsTGTX
TGTX
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
118% more first-time investments, than exits
New positions opened: 96 | Existing positions closed: 44
52% more call options, than puts
Call options by funds: $70.9M | Put options by funds: $46.8M
40% more capital invested
Capital invested by funds: $1.7B [Q2] → $2.38B (+$680M) [Q3]
28% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 72
19% more funds holding
Funds holding: 254 [Q2] → 302 (+48) [Q3]
4.09% more ownership
Funds ownership: 61.63% [Q2] → 65.73% (+4.09%) [Q3]
17% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 5 (-1) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
33%
downside
Avg. target
$40
22%
upside
High target
$55
67%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
HC Wainwright & Co. Edward White 29% 1-year accuracy 43 / 150 met price target | 67%upside $55 | Buy Reiterated | 15 Jan 2025 |
JP Morgan Eric Joseph 48% 1-year accuracy 14 / 29 met price target | 31%upside $43 | Overweight Maintained | 25 Nov 2024 |
Goldman Sachs Corinne Jenkins 33% 1-year accuracy 2 / 6 met price target | 33%downside $22 | Neutral Maintained | 5 Nov 2024 |
Financial journalist opinion
Based on 7 articles about TGTX published over the past 30 days
Positive
Zacks Investment Research
1 week ago
All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy
TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Seeking Alpha
1 week ago
TG Therapeutics: Entering 2025 With Increased Investor Expectations
TG Therapeutics presented at the JP Morgan Healthcare conference this month and CEO Weiss provided commercial and pipeline updates. Briumvi's strong Q4 2024 performance, with $103.6 million in net sales, and 2025 outlook highlight its growth potential despite recent new competition from Roche's Ocrevus Zunovo. Pipeline updates include subcutaneous Briumvi entering phase 3 trials in mid-2025 and new trials to improve IV Briumvi's convenience, alongside expansion into myasthenia gravis.
Positive
Seeking Alpha
2 weeks ago
TG Therapeutics: 2025 Revenues Will Smash Expectations
TG Therapeutics exceeded 2024 revenue guidance by 24%, signaling strong growth and market share capture with its Multiple Sclerosis treatment, Briumvi. 2025 revenue guidance of $540 million implies slower growth, but management and data suggest potential for significantly higher revenue, possibly reaching $605 million. CEO comments and Q4 performance indicate sustained 15-20% new patient growth, bolstered by upcoming advertisements and increased visibility among key opinion leaders.
Positive
Zacks Investment Research
2 weeks ago
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise
TG Therapeutics reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides revenue guidance for 2025 and other pipeline goals.
Positive
Zacks Investment Research
2 weeks ago
TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last?
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Seeking Alpha
3 weeks ago
TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst
TG Therapeutics is already marketing an IV infusion of Briumvi, but is also developing a subcutaneous form, which could help it compete with other multiple sclerosis drugs. The company expects to report initial data on the subcutaneous form of Briumvi in early 2025, which could be positive given the company's upbeat statements on its prospects. While the company has approved a $100M share buyback, it only bought back $2.1M in Q3'24. Further buybacks could limit downside in the stock.
Neutral
GlobeNewsWire
3 weeks ago
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 43rd Annual J.P.
Negative
Market Watch
2 months ago
20 stocks likely to lag the S&P 500 over the next year — for this one reason
Difficult-to-short stocks often trade at artificially inflated, unsustainable prices.
Positive
Investors Business Daily
2 months ago
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Neutral
GlobeNewsWire
2 months ago
TG Therapeutics to Participate in the Evercore HealthCONx Conference
Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET
Charts implemented using Lightweight Charts™